FlowAid Medical Technologies Corp.

FlowAid Medical Technologies Corp. is a medical device company founded in 2015 with a primary focus on addressing the complications arising from inadequate blood flow. The company aims to lead in treating circulatory disorders of the extremities with innovative cutting-edge technologies, ultimately improving the quality of patient care and vascular health care delivery. FlowAid achieves this through the continuous refinement of existing products and the development of new non-invasive medical devices and procedures for increasing blood flow and circulatory enhancement. The FA100 SCCD Sequential Contraction Compression Device received CE mark approval from the European Community on July 7, 2016, followed by Health Canada MDL License No.: 97539 granted on August 18, 2016. The FDA clearance K162987 for the FA100 SCCD was granted on February 14, 2017. The company operates in the Manufacturing and Medical Devices industries. However, there is no publicly available information regarding the last investment or investors in the company.